Starpharma : The Third Installment

Over the past two weeks I copped quite a bit of email flack from devout Starpharma (ASX : SPL) shareholders in response to my last (two) posts. Here is a pithy example: Long Tail, you are just a downramper and a f—–g idiot. You claim to know about science but you can’t see good results…

Starpharma Sensationalism – MkII

As a number of (slightly cocky and goading) readers pointed out today, my prior post on Starpharma’s utterly stupid pre-clinical announcement had a major flaw. In the interest of being comprehensive, I would like to make an additional follow-up comment, while simultaneously acknowledging my own incompetence and stupidity. I was too busy telling you about…

Starpharma Sensationalism

Really? REALLY? Yesterday Starpharma (ASX : SPL) announced that it had done some mouse models with a Herceptin-conjugated DEP dendrimer. It wasn’t peer reviewed data. It wasn’t an exhaustive pre-clinical package. It was just a one-off science experiment packaged up and served to retail investors as company propaganda. 20 mice. The company even states that…

Imugene’s Monster Raise

Following last week’s ASX trading halt request, I have been waiting for the announcement regarding Imugene’s (ASX : IMU) financing. The news came at market open this morning, specifically that the company had placed $3m through the “usual suspects”. Combined with the end-year disclosure, this means the company has about $5m in the bank +/- 10% with a…

Nexvet : Looking after (wo)man’s best friend…

My name is Chris Behrenbruch, and I live with a cat named Kuzya. In case you have wondered why I started this post this way, I figured after taking a look at Nexvet’s management bios on the company website, I would lack credibility if I didn’t also disclose my relationship to the aforementioned moggy. To…